Jie Ting

Value Evidence Strategy & Generation

United States

Senior Director, Cell Therapy RWE & HEOR at Arcellx
Aug 2024 - Present · 2 yrs
Via Seagen acquisition: Senior Director - HTA, Value & Evidence Oncology at Pfizer
Jan 2024 - Jul 2024 · 7 mos
Seagen (Bothell, Washington, United States)
- Senior Director, HEOR, Global Value & Access
  Oct 2022 - Jul 2024 · 1 yr 10 mos
  Franchise lead for 2 products in solid tumor and heme; people manager
- Director, HEOR, Global Value Access & Pricing
  Apr 2020 - Oct 2022 · 2 yrs 7 mos
Gilead Sciences (Foster City, California, United States)
- Associate Director, HEOR
  Nov 2018 - Apr 2020 · 1 yr 6 mos
  Led and strategized global HEOR activities for launching, marketed, and pipeline HIV indications, and HCV products
- Senior Manager, HEOR
  Nov 2017 - Nov 2018 · 1 yr 1 mo
  Generated, communicated, and disseminated US and international value evidence to demonstrate unmet need, value differentiation, and health and economic outcomes for marketed and pipeline Liver (HCV, NASH, PSC) products
Biogen (3 yrs 1 mo)
- Manager, HEOR, Global Value & Access
  Oct 2016 - Oct 2017 · 1 yr 1 mo
  Supported value evidence generation and communication for Alzheimer's disease
- Postdoctoral fellow, Global Market Access, Health Economics and Outcomes Research
  Oct 2014 - Sep 2016 · 2 yrs
  Supported HEOR projects for Neurology and Inflammation disease areas